Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Vancouver, Wash. – Absci Corporation released its first-quarter 2026 financial results on May 7, confirming steady advancement of its lead clinical program while maintaining a disciplined approach to spending. The clinical-stage biotech firm, which uses generative AI to design new antibody therapies, reported progress on its most advanced candidate and introduced an additional program in the same therapeutic area. Executives emphasized that key clinical data readouts remain on schedule for later this year and into 2027.
Lead Program Stays on Track
Absci continues to advance ABS-201, an anti-prolactin receptor antibody developed for androgenetic alopecia, a common form of hair loss. The Phase I/IIa trial has completed dosing of all planned healthy volunteers, and patient enrollment is proceeding as expected. Company leaders noted that the study will generate multiple data updates throughout 2026 and 2027, providing investors with regular visibility into safety and early efficacy signals. The firm also disclosed a new preclinical candidate, ABS-202, which targets the same prolactin pathway. This addition expands the prolactin-focused pipeline without requiring new capital raises at this stage. Oncology programs, by contrast, have been deprioritized to concentrate resources on the most promising opportunities.
Financial Results Reflect Targeted Investment
Revenue for the three months ended March 31 totaled $200,000, down from $1.2 million in the same period a year earlier. The decline stems from the timing of collaboration milestones rather than any change in business fundamentals. Research and development expenses rose to $19.3 million as clinical activities intensified, while selling, general and administrative costs reached $9.1 million. The company posted a net loss of $29.6 million, or $0.19 per share. Cash, cash equivalents and marketable securities stood at $125.7 million at quarter end. Management stated that this balance provides sufficient runway to fund operations into the first half of 2028, covering all planned clinical milestones without additional financing. Key financial highlights include:
– Revenue: $0.2 million
– R&D spending: $19.3 million
– Net loss: $29.6 million
– Cash position: $125.7 million
– Projected runway: into first half of 2028
Strategic Outlook Remains Focused
Absci executives described 2026 as a data-rich period driven by the ABS-201 trial and the emerging ABS-202 program. The company continues to evaluate additional indications within the prolactin pathway while maintaining tight control over operating expenses. No changes were announced to the overall development timeline or capital allocation strategy. Investors will watch upcoming clinical updates closely, as positive signals could influence partnership discussions or valuation. The current cash position gives Absci flexibility to advance its pipeline independently through the next several data readouts.
